8 Nov 2022 , 04:37 PM
Net profit of Jenburkt Pharmaceuticals declined 13.80% to Rs 6.87 crore in the quarter ended September 2022 as against Rs 7.97 crore during the previous quarter ended September 2021. Sales rose 0.96% to Rs 35.85 crore in the quarter ended September 2022 as against Rs 35.51 crore during the previous quarter ended September 2021.
| Particulars | Quarter Ended | ||
| ? | Sep. 2022 | Sep. 2021 | % Var. |
| Sales | 35.85 | 35.51 | 1 |
| OPM % | 24.02 | 28.92 | – |
| PBDT | 9.78 | 11.35 | -14 |
| PBT | 9.24 | 10.90 | -15 |
| NP | 6.87 | 7.97 | -14 |
Powered by Capital Market – Live News
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
